Bupivacaine HCl Injection Recalled Due to Temperature Abuse Manufacturing Defect
Bupivacaine HCl Injection multi-dose vials are being recalled due to temperature abuse during manufacturing. The product was distributed nationwide. Patients should consult their healthcare provider for alternative treatments.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a manufacturing defect (temperature abuse) of an injectable pharmaceutical product. No illnesses or injuries are reported in the source text, making the hazard theoretical rather than confirmed. However, manufacturing integrity is critical for injectable products, warranting a High severity rating.
Plain-English summary
Bupivacaine HCl Injection, 0.25%, supplied in 50 mL multi-dose vials, is being recalled. The product (NDC 55150-0249-50) was manufactured by Auromedics Pharma LLC and distributed nationwide by McKesson Medical-Surgical Inc.
The recall is due to cGMP (current Good Manufacturing Practice) deviations involving temperature abuse. Temperature abuse refers to exposure to improper temperatures during manufacturing or distribution of the product.
The affected product totals 34 cartons, each containing 25 vials. McKesson Medical-Surgical was unable to identify specific lot numbers distributed to individual customers; however, affected customers have been provided with the dates their shipments may have been affected.
Patients and healthcare providers who have received this product should consult with their healthcare provider regarding alternative treatment options.
The recalled product
- Product
- Bupivacaine HCl Injection, Multi dose vial, 0.25%, 50 mL/2.5 mg/mL, Rx only, Manufacturer: Auromedics Pharma LLC, NDC 55150-0249-50
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Hazard
- temperature-abuse
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27